Angiopoietin/Tie signaling regulation of vascular leakage in lung inflammation
血管生成素/Tie信号传导对肺部炎症血管渗漏的调节
基本信息
- 批准号:9927927
- 负责人:
- 金额:$ 63.44万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-07-01 至 2022-05-31
- 项目状态:已结题
- 来源:
- 关键词:ANGPT1 geneAcute Lung InjuryAdmission activityAdult Respiratory Distress SyndromeAgonistAlveolarAlveolar CellAngiopoietin-2AngiopoietinsBiological MarkersBloodBlood VesselsBlood capillariesClinicalCritical IllnessDataDevelopmentDisease modelEndothelial CellsEventExtravasationFOXO1A geneFeedbackFibrinogenGasesGeneticGenetic TranscriptionImpairmentIn VitroIndividualInflammationInflammatoryInfluenzaLeadLungLung InflammationMaintenanceMeasuresMediatingMethodsMicrospheresModelingMonitorMusOrphanOutcomePatientsPharmacologyPhosphorylationPilot ProjectsPlasmaPreventionPrognostic MarkerProtein DephosphorylationReceptor SignalingRegulationSepsisSeveritiesSeverity of illnessSignal PathwaySignal TransductionSiteStimulusTIE-2 ReceptorTestingTranslatingVascular DiseasesVascular PermeabilitiesVascular remodelingVirus DiseasesWorkairway inflammationclinically significantcytokineendothelial dysfunctionexperimental studygain of functionin vivoinfluenzavirusloss of functionlung injurylung vascular injurymortalitymortality riskmouse modelnovelnovel strategiesoverexpressionprognostic significancereceptorvascular contributionsvascular endothelial protein tyrosine phosphatasevascular injury
项目摘要
Angiopoietin/Tie signaling regulation of vascular leakage in lung inflammation
PROJECT SUMMARY
As a central feature of acute lung injury and acute respiratory distress syndrome (ARDS), vascular leakage not
only impairs gas exchange but also initiates a cascade of events that can have fatal consequences. No
treatments are currently available to reduce leakage by stabilizing the lung vasculature. This project will
determine the contributions of angiopoietin-2 (Ang2), orphan receptor Tie1, and VE-PTP, also known as
vascular endothelial protein-tyrosine phosphatase, to the regulation of Tie2 (Tek) receptor signaling and
increased vascular permeability (“leakage”) in lung injury. Building on known anti-leakage effects of
angiopoietin-1 (Ang1) and other Tie2 agonists, the project will target components of a recently described
positive feedback loop that governs the severity of vascular leakage. Inflammatory cytokines that trigger Tie1
receptor ectodomain shedding and inactivation and Tie2 signaling suppression in endothelial cells also
increase Foxo1 transcriptional activity and expression of Ang2, which sustains Tie2 inactivation and leakage.
Aim #1 will explore new approaches for reducing leakage and promoting vascular stability in lung injury by
reversing the suppression of Tie2 signaling in endothelial cells of alveolar capillaries. Experiments will
determine the contributions of Ang2 overexpression, Tie1 ectodomain shedding and inactivation, and VE-PTP-
mediated Tie2 dephosphorylation to Tie2 inactivation and leakage in lung injury. Genetic and pharmacologic
gain- and loss-of-function strategies will be used to activate Tie2, inhibit Ang2, suppress Tie1 ectodomain
shedding, and inhibit VE-PTP activity in the lung vasculature in prevention and reversal trials of sepsis and
influenza virus infection in mice. Tie1, Tie2 phosphorylation, Ang2, VE-PTP, and leakage will be assessed as
readouts. Leakage will be localized and measured by novel methods for visualizing extravasated fibrinogen
and 20-nm fluorescent microspheres at the level of individual alveolar capillaries. Aim #2 will examine the
functional and prognostic significance of elevated circulating levels of soluble Tie1 (sTie1) as a biomarker of
endothelial dysfunction in lung injury. Studies in mice will identify changes in endothelial cell Tie2 signaling that
lead to increased blood levels of sTie1 and how these relate to the severity of leakage from lung capillaries.
Parallel studies of critically ill patients will probe the clinical significance of elevated plasma levels of sTie1 in
sepsis, with or without the development of ARDS. The work will build on data from pilot studies showing 67%
mortality in 23 critically ill patients with elevated plasma levels of sTie1 and Ang2 at admission, compared to
only 8% in those with normal sTie1 and Ang2. Together, the experiments will define the functional benefit of
activating Tie2, inhibiting Ang2, suppressing Tie1 ectodomain shedding, and inhibiting VE-PTP in lung injury,
and will determine the clinical significance of sTie1 as a prognostic biomarker in ARDS.
血管生成素/Tie信号在肺部炎症血管渗漏中的调控作用
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Donald M McDonald其他文献
Imaging of angiogenesis: from microscope to clinic
血管生成成像:从显微镜到临床
- DOI:
10.1038/nm0603-713 - 发表时间:
2003-06-01 - 期刊:
- 影响因子:50.000
- 作者:
Donald M McDonald;Peter L Choyke - 通讯作者:
Peter L Choyke
Title Retrograde Lymph Flow Leads to Chylothorax in Transgenic Mice with Lymphatic Malformations Permalink
标题 逆行淋巴流导致淋巴畸形转基因小鼠出现乳糜胸 永久链接
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
Maximilian Nitschké;Alexander Bell;Sinem Karaman;M. Amouzgar;Joseph M. Rutkowski;Philipp E. Scherer;Kari Alitalo;Donald M McDonald - 通讯作者:
Donald M McDonald
Donald M McDonald的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Donald M McDonald', 18)}}的其他基金
Angiopoietin/Tie signaling regulation of vascular leakage in lung inflammation
血管生成素/Tie信号传导对肺部炎症血管渗漏的调节
- 批准号:
10186794 - 财政年份:2018
- 资助金额:
$ 63.44万 - 项目类别:
Mechanisms, consequences, and reversal of abnormalities in lung lymphatics
肺淋巴管异常的机制、后果和逆转
- 批准号:
9035306 - 财政年份:2015
- 资助金额:
$ 63.44万 - 项目类别:
Lymphangiogenesis and Angiogenesis in Airway Inflammation
气道炎症中的淋巴管生成和血管生成
- 批准号:
8239550 - 财政年份:2011
- 资助金额:
$ 63.44万 - 项目类别:
Lymphangiogenesis and Angiogenesis in Airway Inflammation
气道炎症中的淋巴管生成和血管生成
- 批准号:
7931087 - 财政年份:2010
- 资助金额:
$ 63.44万 - 项目类别:
Lymphangiogenesis and Angiogenesis in Airway Inflammation
气道炎症中的淋巴管生成和血管生成
- 批准号:
7689984 - 财政年份:2009
- 资助金额:
$ 63.44万 - 项目类别:
Angiogenesis and Lymphangiogenesis in Airway Inflammatio
气道炎症中的血管生成和淋巴管生成
- 批准号:
6955252 - 财政年份:2004
- 资助金额:
$ 63.44万 - 项目类别:
MICROVASCULAR REMODELING IN CHRONIC AIRWAY INFLAMMATION
慢性气道炎症的微血管重塑
- 批准号:
6781169 - 财政年份:2003
- 资助金额:
$ 63.44万 - 项目类别:
MICROVASCULAR REMODELING IN CHRONIC AIRWAY INFLAMMATION
慢性气道炎症的微血管重塑
- 批准号:
6616335 - 财政年份:2002
- 资助金额:
$ 63.44万 - 项目类别:
MICROVASCULAR REMODELING IN CHRONIC AIRWAY INFLAMMATION
慢性气道炎症的微血管重塑
- 批准号:
6491088 - 财政年份:2001
- 资助金额:
$ 63.44万 - 项目类别:
MICROVASCULAR REMODELING IN CHRONIC AIRWAY INFLAMMATION
慢性气道炎症的微血管重塑
- 批准号:
6325906 - 财政年份:2000
- 资助金额:
$ 63.44万 - 项目类别:
相似海外基金
Combinatorial cytokine-coated macrophages for targeted immunomodulation in acute lung injury
组合细胞因子包被的巨噬细胞用于急性肺损伤的靶向免疫调节
- 批准号:
10648387 - 财政年份:2023
- 资助金额:
$ 63.44万 - 项目类别:
Inducible HMGB1 antagonist for viral-induced acute lung injury.
诱导型 HMGB1 拮抗剂,用于治疗病毒引起的急性肺损伤。
- 批准号:
10591804 - 财政年份:2023
- 资助金额:
$ 63.44万 - 项目类别:
MAP2K1 AND MAP2K2 IN ACUTE LUNG INJURY AND RESOLUTION
MAP2K1 和 MAP2K2 在急性肺损伤中的作用及缓解
- 批准号:
10741574 - 财政年份:2023
- 资助金额:
$ 63.44万 - 项目类别:
Lung epithelial cell-derived C3 in acute lung injury
肺上皮细胞衍生的 C3 在急性肺损伤中的作用
- 批准号:
10720687 - 财政年份:2023
- 资助金额:
$ 63.44万 - 项目类别:
Examining the role of TRMT1 and tRNA methylation in acute lung injury and ARDS
检查 TRMT1 和 tRNA 甲基化在急性肺损伤和 ARDS 中的作用
- 批准号:
10719249 - 财政年份:2023
- 资助金额:
$ 63.44万 - 项目类别:
Development of a new treatment for COVID-19-related acute lung injury targeting the microbiota-derived peptide corisin
针对微生物群衍生肽 corisin 开发治疗 COVID-19 相关急性肺损伤的新疗法
- 批准号:
23K07651 - 财政年份:2023
- 资助金额:
$ 63.44万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Probing immunovascular mechanobiology in pneumonia-associated acute lung injury at the single capillary level
在单毛细血管水平探讨肺炎相关急性肺损伤的免疫血管力学生物学
- 批准号:
10679944 - 财政年份:2023
- 资助金额:
$ 63.44万 - 项目类别:
The amyloid precursor protein protects against acute lung injury
淀粉样前体蛋白可预防急性肺损伤
- 批准号:
10575258 - 财政年份:2023
- 资助金额:
$ 63.44万 - 项目类别:
Role of macrophages and miRNA in regulating lung macrophage polarization and lung pathogenesis during respiratory virus-induced acute lung injury in normal and diabetic Syrian hamsters.
正常和糖尿病叙利亚仓鼠呼吸道病毒引起的急性肺损伤期间巨噬细胞和 miRNA 在调节肺巨噬细胞极化和肺部发病机制中的作用。
- 批准号:
10701207 - 财政年份:2023
- 资助金额:
$ 63.44万 - 项目类别:
Roles of N-glycans on neutrophil beta2 integrins in progression of acute lung injury
N-聚糖对中性粒细胞β2整合素在急性肺损伤进展中的作用
- 批准号:
10837431 - 财政年份:2023
- 资助金额:
$ 63.44万 - 项目类别:














{{item.name}}会员




